Helen Tayton Martin - Jan 15, 2024 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Role
Chief Business & Strgy Officer
Signature
/s/ Helen Tayton-Martin
Stock symbol
ADAP
Transactions as of
Jan 15, 2024
Transactions value $
$0
Form type
4
Date filed
1/17/2024, 05:01 PM
Previous filing
Jan 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADAP Option to purchase Ordinary Shares Award $0 +2.54M $0.00 2.54M Jan 15, 2024 Ordinary Shares 2.54M $0.14 Direct F1, F2
transaction ADAP Option to purchase Ordinary Shares Award $0 +565K $0.00 565K Jan 15, 2024 Ordinary Shares 565K $0.00 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2 Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.
F3 The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4 Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.